Title
Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer - A Randomized Phase 3 Trial

Description
The usual approach for patients who are not in a study and whose disease has gotten worse is to switch treatments. Sometimes, combinations of drugs or radiotherapy are used. The study doctor can explain which treatment may be best. These treatments can reduce symptoms and may stop the tumour from growing for several months or longer.

Objective
Primary Objective
To evaluate if the addition of SBRT to extra-cranial oligoprogressive metastatic disease can prolong progression-free survival (PFS) and/or overall survival (OS) compared to SOC systemic therapy alone in participants with oligoprogressive NSCLC

Secondary Objectives
To evaluate both treatment strategies with respect to:
Safety and tolerability (using CTCAE Version 5.0)
Participant-reported adverse events (using PRO-CTCAE questionnaire)
Participant-reported quality of life (using EORTC-QLQ-C30 and QLQ-LC13 questionnaires)

Treatment This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs?

This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.

Key Eligibility For full study eligibility, see this study's ClinicalTrials.gov record.

Applicable Disease Sites
Lung

Participating Institutions
Johnson Creek, UW Cancer Center; UW Health Eastpark Medical Center; UW Health University Hospital